These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11750459)

  • 1. Long-term effects of single versus double CsA dosing in kidney transplantation.
    Tarantino A; Montagnino G; Cesana B; Aroldi A; Campise M; Passerini P; Ponticelli C
    Transplant Proc; 2001; 33(7-8):3409-10. PubMed ID: 11750459
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclosporine from twice to single daily dosing: impact on renal function, mortality, and graft loss.
    Bianco PD; Silva HT; Boni R; Machado PG; Pacheco-Silva A; Pestana JO
    Transplant Proc; 2002 Nov; 34(7):2920-1. PubMed ID: 12431657
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cyclosporin in transplantation management--especially after kidney transplantation].
    Quellhorst E
    Internist (Berl); 1996 Jan; 37(1):88-90. PubMed ID: 8837834
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term outcome of kidney transplantation after steroid withdrawal.
    Dunn T; Asolati M; Holman D; Raofi V; Lutrin F; Massad M; Pollak R; Benedetti E
    Transplant Proc; 1998 Aug; 30(5):1788-9. PubMed ID: 9723283
    [No Abstract]   [Full Text] [Related]  

  • 5. Azathioprine can be safely stopped in triple drug induction protocols including cyclosporine and steroids in renal transplantation.
    Pallardó LM; Sánchez J; Sánchez P; García J; Orero E; Beneyto I; Ros F
    Transplant Proc; 1992 Dec; 24(6):2604-5. PubMed ID: 1465880
    [No Abstract]   [Full Text] [Related]  

  • 6. Elective cyclosporine withdrawal in renal transplant recipients maintained on triple therapy.
    Keitel E; Bittar AE; Losekann A; Deboni L; Ceretta F; Goldani JC; Garcia VD
    Transplant Proc; 1992 Dec; 24(6):2606-8. PubMed ID: 1465881
    [No Abstract]   [Full Text] [Related]  

  • 7. Withdrawal versus continuous cyclosporine therapy in kidney transplant recipients of one-haplotype-matched donors.
    Chew-Wong A; Alberú J; Abasta-Jiménez M; Alvarez-Sandoval E; Gabilondo-Navarro F; Correa-Rotter R
    Transplant Proc; 1999; 31(1-2):1106-9. PubMed ID: 10083494
    [No Abstract]   [Full Text] [Related]  

  • 8. A one-year comparative study of Neoral vs Consupren in de novo renal transplant patients.
    Stephan A; Masri MA; Barbari A; Aoun S; Rizk S; Kamel G
    Transplant Proc; 1998 Nov; 30(7):3533-4. PubMed ID: 9838547
    [No Abstract]   [Full Text] [Related]  

  • 9. Relationship between maintenance dose of cyclosporine and long-term kidney graft survival. Collaborative Transplant Study.
    Opelz G
    Transplant Proc; 1998 Aug; 30(5):1716-7. PubMed ID: 9723253
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibody therapy in steroid-resistant rejection.
    Waiser J; Budde K; Schreiber M; Böhler T; Löbermann LA; Neumayer HH
    Transplant Proc; 1998 Aug; 30(5):1778-9. PubMed ID: 9723279
    [No Abstract]   [Full Text] [Related]  

  • 11. Six-year experience with a triple drug protocol in renal transplantation: analysis of risk factors.
    Pallardó LM; Sánchez P; Sánchez J; García J; Orero E; Beneyto I; Cruz JM
    Transplant Proc; 1992 Dec; 24(6):2714-5. PubMed ID: 1465911
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence on the long-term outcome of renal allografts by fosfomycin.
    Hoyer J; Winterhoff R; Fricke L; Sack K
    Transplant Proc; 1997 Nov; 29(7):2948-50. PubMed ID: 9365624
    [No Abstract]   [Full Text] [Related]  

  • 13. Repeated HLA mismatch in multiple kidney transplantation: preliminary results of 146 retransplantations in the cyclosporine era.
    Gnant MF; Sautner T; Rosenmayr A; Muehlbacher F
    Transplant Proc; 1992 Dec; 24(6):2466-8. PubMed ID: 1465833
    [No Abstract]   [Full Text] [Related]  

  • 14. Withdrawal of steroids from a cyclosporine-based regimen: pro.
    Ponticelli C
    Transplant Proc; 1998 Aug; 30(5):1782-4. PubMed ID: 9723281
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of microemulsion form cyclosporine immediately after kidney transplantation without intravenous cyclosporine.
    Jirasiritham S; Sumethkul V; Mavichak V; Jirasiritham S
    Transplant Proc; 1998 Aug; 30(5):1760-1. PubMed ID: 9723270
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of acute rejection episodes on long-term renal graft survival.
    Berczi C; Asztalos L; Kincses Z; Löcsey L; Balázs G
    Transplant Proc; 1998 Aug; 30(5):1775. PubMed ID: 9723277
    [No Abstract]   [Full Text] [Related]  

  • 17. Excellent long-term survival of low-risk, first renal allografts using cyclosporine/azathioprine double therapy.
    Faull RJ; Bannister KM; Russ GR; Mathew TH; Clarkson AR
    Transplant Proc; 1999; 31(1-2):1155-6. PubMed ID: 10083516
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of cyclosporine dosing frequency on graft function and survival after the conversion from sandimmun to neoral in stable kidney transplanted patients.
    Sampaio EL; Park SI; Felipe CR; Silva HT; Pestana JO
    Transplant Proc; 2002 Dec; 34(8):3153-61. PubMed ID: 12493405
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and effectiveness of microemulsion cyclosporine in renal allograft recipients: 1-year follow-up study.
    Park K; Kim MS; Kim SI; Kim YS; Moon JI
    Transplant Proc; 1998 Nov; 30(7):3556-7. PubMed ID: 9838557
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term results and risk factors of quadruple immunosuppression in renal transplantation.
    Hiesse C; Kriaa F; Eschwege P; Boubenider S; Marchand S; Benoit G; Charpentier B
    Transplant Proc; 1999; 31(1-2):1111-2. PubMed ID: 10083496
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.